“…A total of 66 studies published until December 31, 2021, met the inclusion criteria and were included in this review. Of the 66 studies, 20 included Chinese populations 5–9,22–36 (two studies also included Chinese Tibetan individuals 9,22 ), 4 included Indian populations, 19,37–39 2 included Indonesian populations, 14,40 12 included Japanese populations 4,10,20,41–49 (one study also included individuals from Uzbekistan 20 ), 4 included Korean populations, 11,12,50,51 3 included Malaysian populations, 15,16,52 1 included Saudi individuals, 21 18 included Taiwanese individuals, 1,3,13,53–67 1 included Thai individuals, 17 and 1 included Vietnamese individuals 18 . Moreover, we reviewed all the studies examining the relationship between the variants of UGT1A1 and the adverse drug reaction (ADR) or therapeutic efficacy of irinotecan‐based chemotherapy in Asian patients with colon cancer published in PubMed from 2018 to 2021.…”